The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects

No abstract is available for this paper.

• Publication year

  2002

• Venue

  European Journal of Clinical Pharmacology

• Publication date

  2002-04-11

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s00228-002-0445-6PMID 12012142
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients

  2005cited by this paper
• Fluvoxamine-tricyclic antidepressant interaction

  2004cited by this paper
• Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: application to amitriptyline N-demethylation.

  2003cited by this paper
• Cytochromes P450 mediating the N-demethylation of amitriptyline.

  2003cited by this paper
• Relative Contribution of CYP3A to Amitriptyline Clearance in Humans: In Vitro and In Vivo Studies

  2001cited by this paper
• Individual and ethnic differences in CYP2C19 activity in Chinese populations.

  2000cited by this paper
• Ethnic Differences in Drug Metabolism

  2000cited by this paper
• Fluvoxamine-Clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism.

  2000cited by this paper
• Five Distinct Human Cytochromes Mediate Amitriptyline N‐Demethylation In Vitro: Dominance of CYP 2C19 and 3A4

  1998cited by this paper
• Enzyme kinetic analysis and inhibition of amitriptyline N-demethylation in human liver microsomes in vitro 1

  1998cited by this paper
• Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele.

  1997cited by this paper
• Metabolism of amitriptyline with CYP2D6 expressed in a human cell line.

  1997cited by this paper
• Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes.

  1997cited by this paper
• Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients.

  1996cited by this paper
• Regioselectivity and Substrate Concentration‐dependency of Involvement of the CYP2D Subfamily in Oxidative Metabolism of Amitriptyline and Nortriptyline in Rat Liver Microsomes

  1996cited by this paper
• The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways.

  1996cited by this paper
• N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors.

  1995cited by this paper
• Genetic analysis of the S‐mephenytoin polymorphism in a chinese population

  1995cited by this paper
• The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation.

  1994cited by this paper
• Single‐dose kinetics of clomipramine: Relationship to the sparteine and S‐mephenytoin oxidation polymorphisms

  1994cited by this paper
• The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.

  1994cited by this paper
• Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.

  1994cited by this paper
• Fluvoxamine is a potent inhibitor of cytochrome P4501A2.

  1993influential reference
• Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver.

  1993cited by this paper
• A Panel Study. The Metabolism and Pharmacoknetics of Clomipramine: Impact of the Sparteine and Mephenytoin Oxidation Polymorphisms

  1993cited by this paper
• The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study.

  1993cited by this paper
• Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes

  1992cited by this paper
• Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin.

  1991influential reference
• The mephenytoin oxidation polymorphism is partially responsible for the N‐demethylation of imipramine

  1991cited by this paper
• Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin.

  1986influential reference
• Amitriptyline metabolism: Association with debrisoquin hydroxylation in nonsmokers

  1986cited by this paper
• Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients--relationship to the debrisoquine hydroxylation metabolic ratio.

  1985cited by this paper
• Single Oral Dose Pharmacokinetics of Amitriptylinoxide and Amitriptyline in Humans

  1985cited by this paper
• Nortriptyline and debrisoquine hydroxylations in Ghanaian and Swedish subjects

  1984cited by this paper
• Amitriptyline metabolism: Relationship to polymorphic debrisoquine hydroxylation

  1983cited by this paper
• Interindividual differences in amitriptyline demethylation

  1980cited by this paper
• Pharmacokinetics of amitriptyline infused intravenously in man

  1976cited by this paper

• Precision Medicine in Antidepressants Treatment.

  2023cites this paper
• Pharmacogenetic Testing for the Pediatric Gastroenterologist: Actionable Drug–Gene Pairs to Know

  2023cites this paper
• Pharmacogenetic Dose Modeling Based on CYP2C19 Allelic Phenotypes

  2022influential citation
• UKnowledge UKnowledge

  2022cites this paper
• Effects of Pharmacokinetic Gene Variation on Therapeutic Drug Levels and Antidepressant Treatment Response

  2022cites this paper
• Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants

  2021cites this paper
• Enzyme-Mediated Two-Step Regio- and Stereoselective Synthesis of Potential Rapid-Acting Antidepressant (2S,6S)-Hydroxynorketamine

  2020cites this paper
• Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis.

  2020cites this paper
• Quantitative Modeling Analysis Demonstrates the Impact of CYP2C19 and CYP2D6 Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite, Nortriptyline

  2018cites this paper
• Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update

  2017influential citation
• Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine

  2017cites this paper
• Impact of CYP2D6 genotype on amitriptyline efficacy for the treatment of diabetic peripheral neuropathy: a pilot study.

  2017cites this paper
• Metabolism and bioactivation of the tricyclic antidepressant amitriptyline in human liver microsomes and human urine.

  2016cites this paper
• Avaliação da citotoxicidade da amitriptilina e do hypericum perforatum em linhas celulares de epitélio intestinal e hepático : experiência profissionalizante na vertente de farmácia comunitária, hospitalar e investigação

  2015influential citation
• Drug Response Heterogeneity and the Genetic Variability of Cytochrome P450–Metabolizing Enzymes

  2014cites this paper
• Markers of Individual Drug Metabolism: Towards the Development of a Personalized Antidepressant Prescription.

  2014cites this paper
• Clinical applications of CYP genotyping in psychiatry

  2014cites this paper
• Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic

  2013cites this paper
• Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

  2013cites this paper
• Supplement to: Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

  2013cites this paper
• Which Metabolites Circulate ? s

  2013cites this paper
• Pharmacogenetics in Psychiatry

  2012cites this paper
• Interference in Immunoassays Used to Monitor Tricyclic Antidepressants

  2012cites this paper
• Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism

  2011cites this paper
• Do Cytochrome P450 Enzymes Contribute to the Metabolism of Xenobiotics in Human

  2010cites this paper
• Rationalization and prediction of in vivo metabolite exposures: the role of metabolite kinetics, clearance predictions and in vitro parameters

  2010cites this paper
• Metabolism and interactions of pesticides in human and animal in vitro hepatic models

  2010cites this paper
• Extrapyramidal symptoms with concomitant use of amitriptyline and amiodarone in an elderly patient.

  2010cites this paper
• The screening for single nucleotide polymorphisms of CYP3A4 in chronic myelogenous leukemia patients receiving imatinib

  2009cites this paper
• Polymorphism of human cytochrome P450 enzymes and its clinical impact

  2009cites this paper
• Plasma amitriptyline level after acute administration, and driving performance in healthy volunteers

  2008cites this paper
• Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients

  2008cites this paper
• Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects.

  2007cites this paper
• Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.

  2007cites this paper
• The impact of CYP allelic variation on antidepressant metabolism: a review

  2007cites this paper
• Tricyclic antidepressant pharmacology and therapeutic drug interactions updated

  2007cites this paper
• Tricyclic and Other Cyclic Antidepressants

  2007cites this paper
• Review article: the prevalence and clinical relevance of cytochrome P450 polymorphisms

  2007cites this paper
• [The role of CYP2C19 polymorphism in the development of adverse effects to drugs and the risk for diseases].

  2006cites this paper
• Papel del polimorfismo genético CYP2C19 en los efectos adversos a fármacos y en el riesgo para diversas enfermedades

  2006cites this paper
• Cytochrome P450 enzymes— in vitro , in vivo , and in silico studies

  2006cites this paper
• Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice

  2006cites this paper
• TOXICOLOGY RESULTS Pharmacogenetics and Drug-Alcohol Interaction

  2005cites this paper
• INTERPRETATION OF POSTMORTEM TOXICOLOGY RESULTS Pharmacogenetics and Drug-Alcohol Interaction

  2005cites this paper
• Pharmacogenetics of Antidepressant Drug Metabolism and Its Clinical Implications

  2005cites this paper
• Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms

  2004cites this paper
• Toward individualized pharmaceutical care of East Asians: the value of genetic testing for polymorphisms in drug-metabolizing genes.

  2004cites this paper
• The Metabolic Fate of Amitriptyline, Nortriptyline and Amitriptylinoxide in Man

  2004cites this paper
• Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

  2004cites this paper
• Genetic Polymorphisms of Cytochrome P450 Enzymes and the Effect on Interindividual, Pharmacokinetic Variability in Extensive Metabolizers

  2004influential citation
• Individualized Medicine - Implementation of Pharmacogenetic Diagnostics in Antidepressant Drug Treatment of Major Depressive Disorders

  2003cites this paper
• Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders.

  2003cites this paper
• Pharmacogenomics of psychiatric drug treatment.

  2003cites this paper